Drug Trial Radar · NCT06763302
NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
Last checked: Nov 20, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,220
Planned (sponsor's estimate)
Start
Jan 1, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- The Children's Hospital of Zhejiang University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 8, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment. The main questions it aims to answer are: 1. Whether the application of blinatumomab can improve the long-term survival of next generation sequence (NGS) MRD-positive B-ALL children after consolidation therapy? 2. Whether the application of blinatumomab can benefit the NGS MRD-negative B-ALL children after consolidation therapy?
Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia
- Pediatric
- Minimal Residual Disease
- Next Generation Sequencing (NGS)
Interventions
BlinatumomabDrug
The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- event free survivalTime frame: From enrollment to the 3-year after the end of treatment
- Relapse free survivalTime frame: From enrollment to the 3-year after the end of treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.